18F-PSMA-1007与64Cu-PSMA在转移性前列腺癌中的对比
A Comparison of 18F-PSMA-1007 and 64Cu-PSMA in 2 Patients With Metastatic Prostate Cancer.
PubMed 文献 · Clin Nucl Med · 2022-01-01
本文报告两例转移性前列腺癌患者,在18F-PSMA-1007 PET/CT后一天行64Cu-PSMA PET/CT,两种显像剂均提供高质量图像且转移灶检出范围相似。
要点
- 18F-PSMA-1007以泌尿清除少、空间分辨率高为突出特点。
- 64Cu-PSMA半衰期更长,可提供不同分辨率的成像。
- 两例中两种显像剂图像质量高且转移灶检出范围相似。
核心结论
- 在两例转移性前列腺癌患者中,18F-PSMA-1007与64Cu-PSMA PET/CT均显示高质量图像和相似的转移灶检出范围。
研究设计与样本
- 病例报告:两例转移性前列腺癌患者,在18F-PSMA-1007 PET/CT后一天行64Cu-PSMA PET/CT。
主要发现
- 两例患者中,两种显像剂均提供高图像质量,转移灶检出范围相似。
临床怎么用
- 提示64Cu-PSMA可作为半衰期更长、成像分辨率不同的PSMA PET显像选择,但需更大样本验证。
局限性
- 仅为两例患者的病例报告,缺乏系统比较与统计推断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
18F-prostate-specific membrane antigen (PSMA) 1007 is one of the most promising radiotracers for PET imaging in prostate cancer, minimal urinary clearance, and higher spatial resolution, which are the most outstanding features. PSMA can also be labeled with 64Cu, offering a longer half-life and different resolution imaging. We present images of metastatic prostate cancer in two patients, where 64Cu-PSMA PET/CT was performed one day after 18F-PSMA-1007 PET/CT. In the two patients, both radiotracers provided high image quality and a similar range of detection for metastatic lesions.
来源:Clin Nucl Med,查看原文。版权归原作者所有。
引用
- Cardoza-Ochoa DR, Rivera-Bravo B. A Comparison of 18F-PSMA-1007 and 64Cu-PSMA in 2 Patients With Metastatic Prostate Cancer. Clin Nucl Med. 2022. PMID: 34115708. doi:10.1097/RLU.0000000000003758
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。